= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Memarian

MSACL 2018 EU Abstract

Topic: Glycomics

Podium Presentation in the Ether on Wednesday at 11:40 (Chair: Guinevere Lageveen-Kammeijer)

HT UPLC Profiling of Total Plasma N-Glycans in Type II Diabetes Mellitus from Patients and Healthy Individuals in a Ghanaian Population

Elham Memarian (Presenter)
Leiden University medical centre

Presenter Bio(s): I, Elham Memarian, am a PhD student at centre for proteomics and metabolomics in Leiden university medical centre. I was able to be a Master graduated in analytical chemistry from the faculty of chemistry at Shahid Beheshti University (Tehran, Iran).
In June 2017, I started my Glysign PhD project, conducting reaserch at Genos Ltd., Zagreb, Croatia, and the Leiden University Medical Centre (LUMC) in Leiden, the Netherlands. My research is geared towards the quantification of serum protein glycosylation in diabetes.

Authors: Elham Memarian(1), Eric Adua (2), Alyce Russell(2), Irena Trbojeviæ- Akmaèiæ(1),Ivan Gudelj(1),Julija Juriæ(1),Peter Roberts(2),Gordan Lauc(1,3),Wei Wang(2,4,5)
(1)Genos Glycoscience Research Laboratory, 10000 Zagreb, Croatia (2)School of Medical and Health Sciences, Edith Cowan University, 6027, WA, Australia(3)University of Zagreb, Faculty of Pharmacy and Biochemistry, 10000 Zagreb, Croatia (4)School of Public Health, Taishan Medical University, Taian 271000, Shandong, China (5)Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing 100069, China


Aberrant protein glycosylation may reflect changes in cell metabolism of type II diabetes mellitus (T2DM) and offers fresh vistas for discovering potential biomarkers. However, the functional significance of T2DM N-glycan alterations is underexplored, since to date N-glycan profiling studies have been mainly performed in selected populations. Geographically and genetically isolated populations are needed for validation of specific biomarkers.

Financial Disclosure

GrantsyesGrant Agreement number: GlySign — H2020-MSCA-ITN-2016/H2020-MSCA-ITN-2016
SalaryyesGenos Ltd., Zagreb, Croatia
Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: